$2.79
4.10% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

ProQR Therapeutics N.V. Stock price

$2.79
-0.88 23.98% 1M
+1.14 69.09% 6M
+0.81 40.91% YTD
+0.78 38.81% 1Y
-5.39 65.89% 3Y
-6.62 70.35% 5Y
-16.81 85.77% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.11 4.10%
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

Key metrics

Market capitalization $287.94m
Enterprise Value $205.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.62
P/S ratio (TTM) P/S ratio 14.87
P/B ratio (TTM) P/B ratio 8.17
Revenue growth (TTM) Revenue growth 346.02%
Revenue (TTM) Revenue $19.37m
EBIT (operating result TTM) EBIT $-32.65m
Free Cash Flow (TTM) Free Cash Flow $-37.82m
Cash position $99.78m
EPS (TTM) EPS $-0.32
P/E forward negative
P/S forward 16.22
EV/Sales forward 11.59
Short interest 0.23%
Show more

Is ProQR Therapeutics N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ProQR Therapeutics N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ProQR Therapeutics N.V. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a ProQR Therapeutics N.V. forecast:

Buy
83%
Hold
17%

Financial data from ProQR Therapeutics N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
19 19
346% 346%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.60 9.60
5% 5%
50%
- Research and Development Expense 36 36
22% 22%
188%
-30 -30
23% 23%
-153%
- Depreciation and Amortization 3.05 3.05
13% 13%
16%
EBIT (Operating Income) EBIT -33 -33
20% 20%
-169%
Net Profit -26 -26
28% 28%
-134%

In millions USD.

Don't miss a Thing! We will send you all news about ProQR Therapeutics N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProQR Therapeutics N.V. Stock News

Neutral
GlobeNewsWire
19 days ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scie...
Neutral
GlobeNewsWire
2 months ago
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offe...
Neutral
GlobeNewsWire
2 months ago
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering...
More ProQR Therapeutics N.V. News

Company Profile

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Daniel Boer
Employees 156
Founded 2012
Website www.proqr-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today